Many family offices are increasingly active or interested in health related enterprises and the effects that the environment and diet can have on a population’s wellness. Many are doing it with an “impact” lens, where their personal values or interests drive their investment choices and decisions. Speakers gave an overview on the most innovative actions being made in cancer research investing, and provide the pros and cons of GMO investing. The workshop further educated attendees on how investors can build on best practices to make sure impact is realized.
John Warner, Warner Babcock Institute
Michael Melnick, BioAtla
David Balekdjian, Bruckner Group
Impact Investing & ESG Primer
Impact Investing in Cancer Therapies and Treatments
GMOs: The Good, the Bad and the Investable
Investor Spotlight: Next Generation Public Equities Strategies